Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivy Shi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
JAMA Cardiology|May 14, 2025
The Limitations and Risks Associated With Semaglutide Treatment-ReplyIvy Shi, Sadiya S Khan, Dhruv S Kazi
Cancer Informatics|December 17, 2011
Aberrant signaling pathways in squamous cell lung carcinomaIvy Shi, Nooshin Hashemi Sadraei, Zhong-Hui Duan, et al.
BMC Bioinformatics|June 14, 2016
Learning mixed graphical models with separate sparsity parameters and stability-based model selectionAndrew J Sedgewick, Ivy Shi, Rory M Donovan, et al.
American Heart Journal|July 1, 2026
Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023Lucas Marinacci, ZhaoNian Zheng, Michael Liu, et al.
JAMA Cardiology|November 18, 2024
Semaglutide Eligibility Across All Current Indications for US AdultsIvy Shi, Sadiya S Khan, Robert W Yeh, et al.
JAMA Cardiology|September 24, 2025
Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and JapanKosuke Inoue, Sérgio R R Decker, Ivy Shi, et al.
JAMA|July 29, 2024
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk EquationsJames A Diao, Ivy Shi, Venkatesh L Murthy, et al.
Oncotarget|November 17, 2016
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial primingPraveena S Thiagarajan, Xiaoliang Wu, Wei Zhang, et al.
Bioinformatics (Oxford, England)|September 8, 2018
Mixed graphical models for integrative causal analysis with application to chronic lung disease diagnosis and prognosisAndrew J Sedgewick, Kristina Buschur, Ivy Shi, et al.
JAMA Cardiology|February 4, 2026
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US AdultsSusan Hennessy, Joanne Penko, Brandon K Bellows, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
JAMA Cardiology|May 14, 2025
The Limitations and Risks Associated With Semaglutide Treatment-ReplyIvy Shi, Sadiya S Khan, Dhruv S Kazi
Cancer Informatics|December 17, 2011
Aberrant signaling pathways in squamous cell lung carcinomaIvy Shi, Nooshin Hashemi Sadraei, Zhong-Hui Duan, et al.
BMC Bioinformatics|June 14, 2016
Learning mixed graphical models with separate sparsity parameters and stability-based model selectionAndrew J Sedgewick, Ivy Shi, Rory M Donovan, et al.
American Heart Journal|July 1, 2026
Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023Lucas Marinacci, ZhaoNian Zheng, Michael Liu, et al.
JAMA Cardiology|November 18, 2024
Semaglutide Eligibility Across All Current Indications for US AdultsIvy Shi, Sadiya S Khan, Robert W Yeh, et al.
JAMA Cardiology|September 24, 2025
Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and JapanKosuke Inoue, Sérgio R R Decker, Ivy Shi, et al.
JAMA|July 29, 2024
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk EquationsJames A Diao, Ivy Shi, Venkatesh L Murthy, et al.
Oncotarget|November 17, 2016
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial primingPraveena S Thiagarajan, Xiaoliang Wu, Wei Zhang, et al.
Bioinformatics (Oxford, England)|September 8, 2018
Mixed graphical models for integrative causal analysis with application to chronic lung disease diagnosis and prognosisAndrew J Sedgewick, Kristina Buschur, Ivy Shi, et al.
JAMA Cardiology|February 4, 2026
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US AdultsSusan Hennessy, Joanne Penko, Brandon K Bellows, et al.
Pageof 2